VYGR
Voyager Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.89
+3.28%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.86
From 52W high−62.20%
Volume85825.00
Market cap$116.46M
P/E (TTM)—
P/S (TTM)3.4x
Div yield—
Key dataNov 4, 2026
Open
$1.86
From 52W high
−62.20%
Volume
85825.00
Market cap
$116.46M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
35.5
MomentumView details →
1D Return
+3.28%
YTD Return
−53.56%
SummaryUpdated Jun 1, 2026
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a clinical-stage gene therapy company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in November 2015 and has since focused on developing innovative treatments for neurological diseases using advanced gene therapy technologies. Voyager specializes in creating adeno-associated virus (AAV) gene therapies that can cross the blood-brain barrier to deliver therapeutic payloads directly to the central nervous system, addressing some of the most challenging neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
Similar companies
Latest newsMore news →
Voyager Therapeutics, Inc. announced that two posters on its investigational tau-targeted therapies VY1706 and VY7523 are planned for presentation at the CTAD conference in Boston on November 16–19, 2026.8d agoDimensional Fund Advisors LP reduced its stake in Voyager Therapeutics, Inc. by 19.3%, selling 208,931 shares during the quarter, leaving 875,568 shares, as disclosed in a 13F filing.83d ago